GlaxoSmithKline Pharmaceuticals Limited (GSK India) announced steady financial performance for the year ended 31st March 2026, reporting a 2% growth in annual revenue to INR 3,790 crores. Profit After Tax rose by 10% to INR 1,012 crores, with EBITDA margins expanding significantly to 34%. The Board of Directors has recommended a final dividend of Rs. 57 per equity share, reflecting the company’s commitment to delivering sustainable value.
Full-Year Financial Performance
For the fiscal year ended 31st March 2026, GSK India demonstrated resilience and disciplined execution. Despite supply chain challenges that impacted topline growth, the company achieved an annual revenue of INR 3,790 crores. Profitability metrics remained strong, with Profit After Tax (PAT) reaching INR 1,012 crores, a 10% increase over the previous year. EBITDA margins saw a notable expansion of 290 basis points, settling at 34%, driven by strategic pricing and cost management initiatives.
Q4 2025-26 Results
In the final quarter (January to March 2026), the company recorded revenue of INR 989 crores and a PAT of INR 275 crores. EBITDA margins for this quarter showed a positive trajectory, improving by 90 basis points to reach 35%.
Strategic Portfolio Highlights
The company continues to leverage its innovative portfolio to drive growth:
- General Medicines: Key brands including Augmentin, Calpol, and T-Bact maintained leadership positions, with the top four promoted brands outperforming the overall market.
- Vaccines: The business reported strong demand, with Shingrix achieving critical mass within the private pediatric and adult immunization segments.
- Oncology: The portfolio is expanding with Jemperli and Zejula. Notably, Jemperli received first-line approval for advanced and recurrent endometrial cancer. Furthermore, the company has received market authorization for Blenrep, an anti-BCMA ADC therapy for relapsed or refractory multiple myeloma, representing a significant future growth opportunity.
Future Outlook
Managing Director Mr. Bhushan Akshikar noted that the performance signals a key inflection point in the company’s journey toward becoming an innovation-led organization. Moving forward, GSK India remains focused on high-growth therapy areas and scientific rigor to ensure long-term, sustainable profitability.
Source: BSE
